` GILD (Gilead Sciences Inc) vs S&P 500 Comparison - Alpha Spread

GILD
vs
S&P 500

Over the past 12 months, GILD has significantly outperformed S&P 500, delivering a return of 67% compared to the S&P 500's 8% growth.

Stocks Performance
GILD vs S&P 500

Loading
GILD
S&P 500
Add Stock

Performance Gap
GILD vs S&P 500

Loading
GILD
S&P 500
Difference

Performance By Year
GILD vs S&P 500

Loading
GILD
S&P 500
Add Stock

Competitors Performance
Gilead Sciences Inc vs Peers

S&P 500
GILD
ABBV
AMGN
VRTX
CSL
Add Stock

Gilead Sciences Inc
Glance View

Economic Moat
None
Market Cap
132.3B USD
Industry
Biotechnology

Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.

GILD Intrinsic Value
97.11 USD
Overvaluation 9%
Intrinsic Value
Price
Back to Top